Haemonetics Wins FDA Approval for Closure Device
The FDA approved Haemonetics and its new vascular closure device designed for heart and vascular procedures. The PerQseal Elite uses a fully absorbable patch that dissolves over time.
Insights:
Haemonetics secured United States regulatory clearance for its PerQseal Elite vascular closure device, sending its shares up 1.2% in extended trading on Monday evening. The approval arrives months after the medical technology company expanded its portfolio through an acquisition in Ireland earlier in January 2026. The new product directly supports minimally invasive heart procedures by sealing arterial openings without leaving permanent implants.
